A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran.
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A.
Jafari M, et al.
Cost Eff Resour Alloc. 2025 Nov 18;23(1):66. doi: 10.1186/s12962-025-00656-2.
Cost Eff Resour Alloc. 2025.
PMID: 41254760
Free PMC article.
CONCLUSION: The results showed that GLE/PIB is cost-effective compared with the two common medication regimens in Iran, SOF/DCV and SOF/VEL, consistent with Iran's national willingness-to-pay threshold based on one time the GDP per capita, making it a good treatment option …
CONCLUSION: The results showed that GLE/PIB is cost-effective compared with the two common medication regimens in Iran, SOF/DCV and SOF/VEL, …